Dr. Omar Manejwala, Former Hazelden Executive to Head Medical Affairs
LOS ANGELES--(BUSINESS WIRE)-- Catasys, Inc. (CATS) announced today that addiction medicine expert Dr. Omar Manejwala, formerly of Hazelden, one of the world’s largest alcohol and drug dependence treatment centers, has joined Catasys as Senior Vice President & Chief Medical Officer. In this capacity he will be responsible for Catasys’s clinical affairs and continued clinical development of the OnTrak™ program.
Prior to joining Catasys, Dr. Manejwala was Medical Director for Hazelden Foundation. Prior to that, Dr. Manejwala served as associate medical director at The Farley Center at Williamsburg Place in Virginia, an addiction treatment center. He is a fellow of the American Psychiatric Association and a diplomate of the American Board of Addiction Medicine. A graduate of the University of Maryland School of Medicine, he completed his residency at Duke University where he served as executive chief resident. Dr. Manejwala's background also includes an MBA from the University of Virginia's Darden School.
“I am excited to be joining Catasys as Catasys is preparing to launch its latest health plan contract”, said Dr. Omar Manejwala. “The Company’s program is the leading edge in addressing addiction clinically and lowering the overall costs by addressing this chronic disease in an integrated medical and behavioral fashion over a 52 week period. With the Company now enrolling members under its health plan contracts we will be focusing on using the outcomes from these members to further the development of Catasys.”
One of today's addiction medicine experts, Dr. Manejwala has been interviewed on Good Morning America, 20/20, ABC World News Tonight, The CBS Early Show, CBS Evening News with Katie Couric, ABC News Primetime, the UK's Sky News, and the international RTL Network. He has also been featured in articles by The New York Times, Chicago Tribune, Los Angeles Times, and the UK's Guardian.
About Catasys®
Catasys, Inc. provides specialized health management services to health plans, employers and unions through a network of licensed and company managed health care providers. The Catasys substance dependence program was designed to address substance dependence as a chronic disease. The program seeks to lower costs and improve member health through the delivery of integrated medical and psychosocial interventions in combination with long term care coaching, including a proprietary treatment program for alcoholism and stimulant dependence. For further information, please visit www.catasyshealth.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, changes in regulations or issuance of new regulations or interpretations, limited operating history and lack of outcomes and statistically significant formal research studies, difficulty enrolling members in our programs, the risk that treatment programs might not be effective, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and substantial regulation in the health care industry; and additional risks factors as discussed in the reports filed by the company with the Securities and Exchange Commission, which are available on its website at http://www.sec.gov.
CONTACT:
Investor Relations:
Catasys, Inc.
Patricia Rouhafza, (310) 444-4333
[email protected]
KEYWORDS: United States North America California
INDUSTRY KEYWORDS: Health Hospitals Other Health General Health Managed Care
MEDIA: